INNOVACAP1,165.00

Innova Captab Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersMOREPENLABIOLCPFDCSENORESSANOFIORCHPHARMAGUJTHEMRPGLIFEMcap ₹6,667 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations282.9302.5262.6294.3318.2316.5314.7351.5380.4450.3447.8470.9
Other Income3.32.35.72.12.24.33.44.54.21.71.62.0
Total Income286.3304.8268.3296.4320.4320.8318.1356.0384.6451.9449.4472.9
Expenses
+ Cost of Materials Consumed178.7190.9160.1188.1205.0195.8210.9229.4233.9280.8261.2308.0
+ Purchases of Stock-in-Trade9.46.012.08.514.311.25.35.05.615.132.612.4
+ Changes in Inventories3.35.1-3.82.6-12.33.0-18.2-13.84.0-4.12.8-16.5
+ Employee Benefit Expense24.225.625.924.928.228.235.539.141.743.842.644.8
+ Finance Costs8.86.80.80.10.10.22.02.95.54.04.64.4
+ Depreciation & Amortisation4.84.93.44.95.05.19.811.011.311.411.411.7
+ Other Expenses26.830.230.428.133.331.833.539.643.245.343.449.1
Total Expenses256.1269.6228.8257.1273.6275.2278.8313.3345.3396.3398.7413.9
EBITDA40.544.638.142.249.746.647.752.151.969.465.173.1
EBIT35.739.734.737.344.741.437.941.140.558.053.761.4
Profit
PBT before Exceptional Items30.235.239.539.346.845.639.342.739.255.750.759.0
Pretax Income30.235.239.539.346.845.639.342.739.255.750.759.0
+ Current Tax7.27.57.85.79.47.73.96.35.59.44.411.0
+ Deferred Tax0.12.63.04.12.43.75.85.44.14.18.23.9
Tax Expense7.310.110.89.811.811.49.711.79.613.512.614.9
Net Income22.925.128.729.535.034.229.631.029.742.138.144.1
+ Net Income — Continuing Ops22.925.128.729.535.034.229.631.029.742.138.144.1
+ Other Comprehensive Income0.10.01.6-0.10.0-0.00.40.0-0.50.60.20.2
Total Comprehensive Income23.025.130.329.435.034.229.931.029.242.838.344.3
Per Share
Basic EPS4.774.395.025.156.125.975.175.425.187.376.657.71
Diluted EPS4.774.395.025.156.125.975.175.425.187.376.657.71
Other Comprehensive Income — detail
+ Other Comprehensive Income0.40.0-0.50.60.20.2
+ Items NOT to be Reclassified to P&L0.10.0-0.1-0.0-0.10.60.0-0.50.60.20.2
+ Tax on Items NOT to be Reclassified0.20.00.00.00.00.0
+ Tax on Items NOT to be Reclassified — alt tag0.00.0-1.6-0.0-0.0-0.1
Per Share — as-filed variants
Basic EPS — Continuing Operations4.774.395.025.156.125.975.175.425.187.376.657.71
Diluted EPS — Continuing Operations4.774.395.025.156.125.975.175.425.187.376.657.71
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit91.5100.494.495.1111.2106.5116.7130.8136.8158.5151.1167.0
Gross Margin %32.3333.1935.9332.3234.9533.6637.0837.2135.9635.1933.7535.46
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)30.235.239.539.346.845.639.342.739.255.750.759.0
Net Income Adj (tax-effected)22.925.128.729.535.034.229.631.029.742.138.144.1
EPS Adj4.774.395.025.156.125.975.175.425.187.376.657.71
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.00
Filed Debt Equity0.010.00
Filed Dscr0.020.00
Filed Iscr0.050.00
Paid Up Equity Capital48.057.257.257.257.257.257.257.257.257.257.257.2
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.